Cancer Research Communications | American Association for Cancer Research

Skip Nav Destination

Editors-In-Chief

Elaine R. Mardis, PhD
Nationwide Children's Hospital
The Ohio State University

Lillian L. Siu, MD
Princess Margaret Cancer Centre
University of Toronto

SUBMIT TO JOURNAL EDITORS

Editors-In-Chief

Elaine R. Mardis, PhD
Nationwide Children's Hospital
The Ohio State University

Lillian L. Siu, MD
Princess Margaret Cancer Centre
University of Toronto

SUBMIT TO JOURNAL EDITORS

Editors' Corner

Spotlight on Breast Cancer at Cancer Research Communications and the SABCS

The 2021 San Antonio Breast Cancer Symposium (SABCS) took place December 7–10, 2021 and was attended by thousands of participants, both virtually and in person. The SABCS, which has occurred annually...(read more)

Journal Sections

Cancer Research Communications welcomes high-quality research spanning the full spectrum of cancer science and medicine. This open access journal expands the AACR journal portfolio, stimulates the exchange of new ideas and approaches, and provides a rapid publication pathway. The below sections reflect the breadth of this new journal’s scope.

Molecular and Cellular Biology

Tumor Biology

Immuno-oncology

Emerging Technologies and Data Science

Therapeutic Research and Development

Precision Medicine and Biomarkers

Clinical Research and Trials

Epidemiology and Prevention

Health Disparities and Outcomes Research

Featured Articles

Molecular and Cellular Biology

A Phenogenetic Axis that Modulates Clinical Manifestation and Predicts Treatment Outcome in Primary Myeloid Neoplasms

Qiujin Shen, Yahui Feng et al.

Although the concept of “myeloid neoplasm continuum” has long been proposed, few comparative genomics studies directly tested this hypothesis. Here we report a multi-modal data analysis of 730 consecutive newly diagnosed patients with primary myeloid neoplasm, along with 462 lymphoid neoplasm cases serving as the ...

Browse Section

Go to Section

Tumor Biology

The Tumor Immune Profile of Murine Ovarian Cancer Models: An Essential Tool For Ovarian Cancer Immunotherapy Research.

Galaxia M Rodriguez, Kristianne J.C. Galpin et al.

Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer with an imperative need for new treatments. Immunotherapy has had marked success in some cancer types; however, clinical trials studying the efficacy of immune checkpoint inhibitors for the treatment of EOC benefited less than 15% of patients. Given ...

Browse Section

Go to Section

Immuno-oncology

The Tumor Immune Profile of Murine Ovarian Cancer Models: An Essential Tool For Ovarian Cancer Immunotherapy Research.

Galaxia M Rodriguez, Kristianne J.C. Galpin et al.

Browse Section

Go to Section

Emerging Technologies and Data Science

Targeting the ezrin adaptor protein sensitizes metastatic breast cancer cells to chemotherapy and reduces neoadjuvant therapy-induced metastasis

Victoria Hoskin, Abdi Ghaffari et al.

The main cause of cancer-associated death is the spread of cancer cells to distant organs. Despite its success in the primary tumor setting, modern chemotherapeutic strategies are rendered ineffective at treating metastatic disease, largely due to the development of resistance. The adaptor protein ezrin has been shown to ...

Browse Section

Go to Section

Therapeutic Research and Development

8-Azaadenosine and 8-Chloroadenosine are not Selective Inhibitors of ADAR

Kyle A. Cottrell, Luisangely Soto-Torres et al.

The RNA editing enzyme ADAR is an attractive therapeutic target for multiple cancers. Through its deaminase activity, ADAR edits adenosine to inosine in double-stranded RNAs. Loss of ADAR in some cancer cell lines causes activation of the type I IFN pathway and the PKR translational repressor, leading to inhibition of ...

Browse Section

Go to Section

Precision Medicine and Biomarkers

Comprehensive Immunoprofiling of High-Risk Oral Proliferative and Localized Leukoplakia

Glenn J. Hanna, Alessandro Villa et al.

Oral leukoplakia is common and may, in some cases, progress to carcinoma. Proliferative leukoplakia is a progressive, often multifocal subtype with a high rate of malignant transformation compared with the more common localized leukoplakia. We hypothesized that the immune microenvironment and gene expression patterns ...

Browse Section

Go to Section